Provexis PLC (GB:PXS)
LSE:PXS
PXS Stock Chart & Stats
0.71 p
0.02 p(3.46%)
At close: 4:00 PM EST
0.71 p
0.02 p(3.46%)
Day’s Range― - ―
52-Week Range0.40 p - 1.55 p
Previous CloseN/A
Volume299.72K
Average Volume (3M)426.62K
Market Cap
£22.87M
Enterprise Value22.35M
Total Cash (Recent Filing)£708.09K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,345,891,400
10 Day Avg. Volume0
30 Day Avg. Volume426,617
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)7.92
Price to Sales (P/S)7.95
P/FCF Ratio-30.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet materially lowers refinancing and interest-rate risk, giving Provexis flexibility to fund commercialization or absorb short-term cash burn without immediate reliance on external lenders. This structural strength supports strategic options over the next several months while revenues scale.
Accelerating Revenue GrowthSharp revenue acceleration, even off a small base, signals improving commercial traction and partner adoption of the company's ingredient/IP. If sustained, this trend can progressively cover fixed costs, improve operating leverage and create durable momentum for margin recovery and cash generation over the medium term.
IP-driven B2B Licensing ModelA licensing and ingredient-supply model is capital-light and scalable: royalties and partner-led product launches let Provexis leverage larger firms' distribution and marketing spend. Structurally, this model can deliver high incremental margins and recurring revenue as partners commercialize products.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow creates ongoing funding risk and may force dilutive equity raises or constrained investments. Even with improving top-line trends, continued cash burn undermines independent growth and can limit the company's ability to scale partner relationships or fund regulatory/commercial milestones.
Large Operating Losses And Weak MarginsVery large negative operating and net margins indicate unit economics are currently unfavorable and profitability is unproven. Without material margin improvement from scale, pricing or cost reductions, losses will persist and constrain retained earnings, partner confidence, and the company’s ability to reinvest in commercial expansion.
Very Small Organizational ScaleAn extremely small team limits execution capacity across commercialization, regulatory, and partner-management functions. Reliance on a tiny workforce raises operational risk, creates single-point dependencies, and may slow project delivery or scaling unless the company commits to sustained hiring or outsources key capabilities.
Provexis News
PXS FAQ
What was Provexis PLC’s price range in the past 12 months?
Provexis PLC lowest share price was 0.40 p and its highest was 1.55 p in the past 12 months.
What is Provexis PLC’s market cap?
Provexis PLC’s market cap is £22.87M.
When is Provexis PLC’s upcoming earnings report date?
Provexis PLC’s upcoming earnings report date is Sep 25, 2026 which is in 173 days.
How were Provexis PLC’s earnings last quarter?
Currently, no data Available
Is Provexis PLC overvalued?
According to Wall Street analysts Provexis PLC’s price is currently Overvalued.
Does Provexis PLC pay dividends?
Provexis PLC does not currently pay dividends.
What is Provexis PLC’s EPS estimate?
Provexis PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Provexis PLC have?
Provexis PLC has 2,345,891,400 shares outstanding.
What happened to Provexis PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Provexis PLC?
Currently, no hedge funds are holding shares in GB:PXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Provexis PLC
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.